**Table S1: Demographic, clinical characteristics, and response to treatment of patients with and without chromosome 21 abnormalities (n=37)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | **Positive Ch.21 abn.** | | **Negative**  **Ch.21 abn.** | **p-value** |
| **Age** | Children | 10 (55.6%) | | 8 (44.4%) | 0.070 |
|  | Adults | 5 (26.3%) | | 14 (73.7%) |  |
| **Sex** | Male | 12 (42.9%) | | 16 (57.1%) | 0.613 |
|  | Female | 3 (33.3%) | | 6 (66.7%) |  |
| **BM cellularity** | Normocellular | 7 (70.0%) | | 3 (30.0%) | 0.056 |
|  | Hypercellular | 8 (29.6%) | | 19 (70.4%) |  |
| **Immunophenotyping** | B-lymphoid/myeloid | 11 (39.3%) | | 17 (60.7%) | 0.784 |
|  | T-lymphoid/myeloid | 4 (44.4%) | | 5 (55.6%) |  |
| **Modal chromosome number** | Hypodiploid | 0 (0.0%) | | 3 (100.0%) | 0.005 |
| Diploid | 6 (27.3%) | | 16 (72.7%) |  |
| Hyperdiploid | 9 (75.0%) | | 3 (25.0%) |  |
| **Complete Remission** | Yes | | 13 (48.1%) | 14 (51.9%) | 0.153 |
|  | No | | 2 (20.0%) | 8 (80.0%) |  |
| **MRD on day 42** | < 0.1% | | 4 (66.7%) | 2 (33.3%) | 0.474 |
|  | ≥ 0.1% | | 9 (39.1%) | 14 (60.9%) |  |

Data are expressed as number (%)

**Table S2: Disease-free survival of the patients who entered complete remission (n=57) in relation to prognostic factors.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **n** | **n events** | **Cumulative survival proportion (%)** | **Median survival (months)** | **p-value** |
| All cases | 57 | 36 | 42.7 | 9.4 (4.4-14.3) |  |
| BCR-ABL |  |  |  |  |  |
| Positive | 8 | 5 | 41.7 | 7.6 (0.7-14.5) | 0.999 |
| Negative | 49 | 31 | 42.4 | 9.4 (4.1-14.7) |  |
| Age group |  |  |  |  |  |
| Children | 29 | 16 | 53.6 | 14.8 (0.0-47.4) | 0.291 |
| Adults | 28 | 20 | 60.7 | 7.6 (2.8-12.4) |  |
| Sex |  |  |  |  |  |
| Male | 44 | 28 | 34.3 | 9.4 (1.1-17.8) | 0.950 |
| Female | 13 | 8 | 33.3 | 5.6 (1.5-9.7) |  |
| Immunophenotype |  |  |  |  |  |
| B/myeloid | 45 | 27 | 45.2 | 9.4 (4.2-14.7) | 0.281 |
| T/myeloid | 12 | 9 | 33.3 | 3.3 (2.3-4.2) |  |
| Cytogenetics (n=27) |  |  |  |  |  |
| Normal | 3 | 3 | 33.3 | 4.0 (1.9-6.2) | 0.473 |
| Abnormal | 24 | 14 | 45.3 | 9.4 (0.0-21.1) |  |
| CTH |  |  |  |  |  |
| Myeloid | 44 | 30 | 38.7 | 9.4 (3.6-15.1) | **0.086** |
| Lymphatic | 13 | 6 | 53.8 | \* |  |
| Imatinib |  |  |  |  |  |
| Yes | 47 | 28 | 46.4 | 9.4 (1.2-17.7) |  |
| No | 10 | 8 | 24.0 | 5.6 (1.8-9.4) | 0.455 |
| BMT |  |  |  |  |  |
| Yes | 52 | 33 | 40.7 | 9.4 (5.0-13.7) |  |
| No | 5 | 3 | 60.0 | 17.6 (0.0-45.6) | 0.581 |
| Ch.21 abn. (n=27) |  |  |  |  |  |
| Yes | 13 | 6 | 56.1 | 14.8 (0.0-29.6) |  |
| No | 14 | 11 | 34.3 | 4.0 (3.5-4.6) | 0.183 |

\* Median survival cannot be calculated

BMT: Bone marrow transplantation